|Mr. Robert A. Berman||CEO & Director||415.81k||N/A||1963|
|Mr. Craig Thomas Glynn||CFO & Treasurer||143k||N/A||1961|
|Dr. Marc H. Glickman||Sr. VP & Chief Medical Officer||403.98k||N/A||1949|
|Mr. Warren Hancock||Co-founder||N/A||N/A||N/A|
|Dr. Benedict Broennimann M.D.||Chief Medical Officer of Outside of United States||N/A||N/A||1957|
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. operates as a subsidiary of Leman Cardiovascular SA.
Hancock Jaffe Laboratories, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.